Linked Life Data

20307981

Source:http://linkedlifedata.com/resource/pubmed/id/20307981

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2010-4-5
pubmed:abstractText
Peroxisome proliferator-activated receptor gamma (PPARgamma) is involved in glucose and lipid homeostasis. PPARgamma agonists are in clinical use for the treatment of type 2 diabetes. Lately, a new class of selective PPARgamma modulators (SPPARgammaMs) was developed, which are believed to show less side effects than full PPARgamma agonists. We have previously shown that alpha-substitution of pirinixic acid, a moderate agonist of PPARalpha and PPARgamma, leads to low micromolar active balanced dual agonists of PPARalpha and PPARgamma. Herein we present modifications of pirinixic acid leading to subtype-selective PPARgamma agonists and furthermore the development of a selective PPARgamma modulator guided by molecular docking studies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1464-3405
pubmed:author
pubmed:copyrightInfo
Copyright 2010 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2469-73
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator.
pubmed:affiliation
Institute of Pharmaceutical Chemistry, ZAFES/LiFF/FIRST, Goethe-University Frankfurt, 60438 Frankfurt, Germany. schubert-zsilavecz@pharmchem.uni-frankfurt.de
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't